Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Blood

Volumn 118, Issue 14, 2011, Pages 3818-3823

  Ravandi, Farhad ^a   O'Brien, Susan ^a   Jorgensen, Jeffrey ^a   Pierce, Sherry ^a   Faderl, Stefan ^a   Ferrajoli, Alessandra ^a   Koller, Charles ^a   Challagundla, Pramoda ^a   York, Sergernne ^a   Brandt, Mark ^a   Luthra, Rajyalakshmi ^a   Burger, Jan ^a   Thomas, Deborah ^a   Keating, Michael ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CLADRIBINE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR; LEVOFLOXACIN; PROTEIN P53; RITUXIMAB; VALACICLOVIR;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELLULITIS; CLINICAL ARTICLE; CLONE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA RELAPSE; MALE; MINIMAL RESIDUAL DISEASE; MONOSOMY; MONOSOMY 17; NAUSEA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SPLENOMEGALY; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 80053649383     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-351502     Document Type: Article

References (31)

1. Golomb HM. Hairy cell leukemia: treatment successes in the past 25 years. J Clin Oncol. 2008;26(16):2607-2609.
2. Freireich EJ, Kurzrock R. The role of investigational therapy in management of patients with advanced metastatic malignancy. J Clin Oncol. 2009;27(2):304-306.
3. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322(16):1117-1121. (Pubitemid 20149529)
4. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol. 1989;7(2):168-172. (Pubitemid 19048448)
5. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92(6):1918- 1926. (Pubitemid 28446680)
6. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13(4):974-982.
7. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733-740.
8. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000;96(9):2981-2986.
9. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21(5):891-896. (Pubitemid 46606450)
10. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104(11):2442-2448. (Pubitemid 41691566)
11. Zinzani PL, Pellegrini C, Stefoni V, et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer. 2010;116(20):4788-4792.
12. Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood. 1996;87(4):1556-1560.
13. Sausville JE, Salloum RG, Sorbara L, et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol. 2003;119(2):213-217. (Pubitemid 37047876)
14. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107(12):4658-4662. (Pubitemid 43882611)
15. Arons E, Margulies I, Sorbara L, et al. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res. 2006;12(9):2804-2811.
16. Grever MR. How I treat hairy cell leukemia. Blood. 2010;115(1):21-28.
17. Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood. 2010;115(10):1893-1896.
18. Ravandi F. Chemo-immunotherapy for hairy cell leukemia. Leuk Lymphoma. 2011;52(suppl 2):72-74.
19. Piris M, Foucar K, Mollejo M, Campo E, Falini B. Splenic B-cell lymphoma/leukaemia, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008.
20. Theriault C, Galoin S, Valmary S, et al. PCR analysis of immunoglobulin heavy chain (IgH) and TcR-gamma chain gene rearrangements in the diagnosis of lymphoproliferative disorders: results of a study of 525 cases. Mod Pathol. 2000;13(12):1269-1279. (Pubitemid 32014663)
21. Campbell MJ, Zelenetz AD, Levy S, Levy R. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol. 1992;29(2):193-203.
22. Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ. Soluble CD22 as a tumor marker for hairy cell leukemia. Blood. 2008;112(6):2272-2277.
23. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23(6):1088-1095. (Pubitemid 46202263)
24. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003-4008. (Pubitemid 44920177)
25. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol. 2009;27(10):1607-1614.
26. Van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853-2858.
27. Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood. 2009;114(21):4696-4702.
28. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114(21):4687-4695.
29. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-4479.
30. Arons E, Roth L, Sapolsky J, Suntum T, Stetler-Stevenson M, Kreitman RJ. Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood. 2011;117(18):4844-4851.
31. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-2315.